Compendium of the most significant studies with reference to properties, intake, effects.

Patrignani P, Capone ML, Tacconelli S. Clinical pharmacology of etoricoxib: a novel selective COX2 inhibitor. Expert Opin Pharmacother. 2003 Feb;4(2):265-84. doi: 10.1517/14656566.4.2.265.

Abstract. The development of COX2 inhibitors with improved biochemical selectivity (such as etoricoxib and valdecoxib) over that of commercially available coxibs has been driven by the potential advantage of safety using higher coxib doses for increased efficacy. Etoricoxib has been approved in the UK as a once-daily medicine for symptomatic relief in the treatment of osteoarthritis (OA), rheumatoid arthritis (RA) and acute gouty arthritis. It is currently approved with additional indications (i.e., for relief of acute pain associated with dental surgery, for primary dysmenorrhoea and for chronic musculo-skeletal pain, including chronic lower-back pain) in Mexico, Brazil and Peru....

la Torre LF, Franco-González DL, Brennan-Bourdon LM, Molina-Frechero N, Alonso-Castro ÁJ, Isiordia-Espinoza MA. Analgesic Efficacy of Etoricoxib following Third Molar Surgery: A Meta-analysis. Behav Neurol. 2021 Sep 8;2021:9536054. doi: 10.1155/2021/9536054. 

Abstract. The purpose of this meta-analysis was to assess the clinical efficacy of etoricoxib in comparison with traditional NSAIDs for postoperative pain after third molar surgery.

Leclercq P, Malaise MG. Le médicament du mois. Etoricoxib (Arcoxia) [Etoricoxib (Arcoxia)]. Rev Med Liege. 2004 May;59(5):345-9. 

Abstract. Etoricoxib (Arcoxia) is a novel non steroidal anti-inflammatory drug (NSAID) that selectively inhibits the inducible form of cyclo-oxygenase (COX), COX-2. Etoricoxib has a higher COX-1/COX-2 selectivity ratio than the other COX-2-selective NSAIDs as rofecoxib, valdecoxib or celecoxib. Tablets of 60, 90 and 120 mg are available. The recommended dosage of etoricoxib is 60 mg/day for osteoarthritis, 90 mg/day for rheumatoid arthritis and 120 mg/day for acute gouty arthritis. Etoricoxib's efficacy has been widely studied in comparative studies, showing the same efficacy as non-COX-2 selective NSAID, with fewer gastro-intestinal adverse effects.

Wang R. Etoricoxib may inhibit cytokine storm to treat COVID-19. Med Hypotheses. 2021 May;150:110557. doi: 10.1016/j.mehy.2021.110557.

Abstract. This article introduces a potential repositioning of the existing drug etoricoxib, which may inhibit cytokine storm to treat COVID-19 through reducing the activity of Cyclooxygenase-2 in the conversion of arachidonic acid to prostaglandin.

Martina SD, Vesta KS, Ripley TL. Etoricoxib: a highly selective COX-2 inhibitor. Ann Pharmacother. 2005 May;39(5):854-62. doi: 10.1345/aph.1E543. 

Abstract. All clinical trials published in English evaluating etoricoxib were included in this review. An abstract was excluded if it presented preliminary data from trials that are now published, analyzed data previously reported in a published clinical trial, or compared etoricoxib with placebo for an indication with published active-comparator controlled trials.

Brigham NC, Nofsinger R, Luo X, Dreger NZ, Abel AK, Gustafson TP, Forster SP, Hermans A, Ji RR, Becker ML. Controlled release of etoricoxib from poly(ester urea) films for post-operative pain management. J Control Release. 2021 Jan 10;329:316-327. doi: 10.1016/j.jconrel.2020.11.052.

Abstract. ...Herein, we report the use of bio-resorbable poly(ester urea) (PEU) films that controllably deliver a non-opioid COX-2 inhibitor, etoricoxib, in vivo and in vitro as a model system for post-surgical pain control....

Liao H, Ou S, Dong X, Liu J, Xiao C. Association of Etoricoxib treatment and incident hypoxia in patients with aortic dissection undergoing endovascular aortic repair. Biomed Pharmacother. 2021 Jul;139:111625. doi: 10.1016/j.biopha.2021.111625. 

Abstract. To assess the efficacy and adverse effects of single dose etoricoxib for acute postoperative pain using methods that permit accurate comparison with other analgesics evaluated in the same way, using criteria of efficacy recommended by in-depth studies at the individual patient level.

Takemoto JK, Reynolds JK, Remsberg CM, Vega-Villa KR, Davies NM. Clinical pharmacokinetic and pharmacodynamic profile of etoricoxib. Clin Pharmacokinet. 2008;47(11):703-20. doi: 10.2165/00003088-200847110-00002.

Abstract.  Etoricoxib has demonstrated a significant reduction in gastrointestinal toxicity compared with many traditional NSAIDs. The renal adverse effects of etoricoxib appear to be similar to those of other NSAIDs, and the cardiovascular adverse effects of this selective COX-2 inhibitor require further clinical scrutiny. Further study is necessary to delineate the relevance of the pharmacokinetic disposition in terms of the clinical benefits and risks of etoricoxib compared with other options in the clinical arsenal.

Burgos Pratx L, Santoro D, Coca Mogro B, Valiente VL, Camino P, Scordo W, Salamone H. Etoricoxib-induced immune hemolytic anemia: first case presenting acute kidney failure. Transfusion. 2019 May;59(5):1657-1660. doi: 10.1111/trf.15226.

Abstract... Etoricoxib must be considered as a possible cause of acute kidney failure in cases of immune hemolytic anemia.

Chilet-Rosell E, Ruiz-Cantero MT, Horga JF. Women's health and gender-based clinical trials on etoricoxib: methodological gender bias. J Public Health (Oxf). 2009 Sep;31(3):434-45. doi: 10.1093/pubmed/fdp024. 

Abstract. The aim of this study was to determine compliance with published good practice guidelines for gender and clinical trials using etoricoxib. The rationale for choosing etoricoxib was that it is widely used by women and there is evidence of potential interaction with contraceptives and hormone replacement therapy as highlighted in the product characteristics.

Aldington S, Shirtcliffe P, Weatherall M, Beasley R. Systematic review and meta-analysis of the risk of major cardiovascular events with etoricoxib therapy. N Z Med J. 2005 Oct 7;118(1223):U1684.

Abstract.  Objective: To determine the risk of thromboembolic cardiovascular events associated with the use of etoricoxib, a COX-2 inhibitor. Design: Systematic review and meta-analysis of placebo-controlled randomised double-blind clinical trials of etoricoxib that were of at least 6 weeks duration and presented data on cardiovascular thromboembolic events.